key: cord-0824484-3nkrxs4h
authors: Ferrara, Francesco; Pianesi, Laura; Vitiello, Antonio
title: COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified
date: 2021-04-15
journal: Immunol Res
DOI: 10.1007/s12026-021-09193-5
sha: aadafc9cda5a3719ed48fbdc9f673860aef82a0e
doc_id: 824484
cord_uid: 3nkrxs4h

nan

vaccines still be effective? Or will there be a need for periodic booster vaccinations? As is the case with flu vaccines? In addition, new monoclonal antibodies directed against the spike protein of SARS-CoV-2 have recently been authorized, through their mechanism of action, prevent endocellular penetration, and reduce viral load. These monoclonal antibodies are indicated for adult patients with COVID-19 comorbidities and risk of hospitalization [6, 7] , but their precise role on the right timing of administration and in which individuals to administer them, or at what stage of the disease, probably remain to be fully identified. Furthermore, are monoclonal antibodies effective against SARS-CoV-2 variants? These important questions remain to be clarified. Certainly, the availability of COVID-19 vaccines and monoclonal antibodies directed against SARS-CoV-2 represent potential therapeutic weapons to halt the global pandemic permanently; however, clinical trials are urgently needed to further clarify important aspects.

A novel coronavirus outbreak of global health concern

Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19

Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discovery Today

Remdesivir versus ritonavir/lopinavir in COVID-19 patients

Remdesivir versus ritonavir/lopinavir in COVID-19 patients

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Neutralizing monoclonal antibody for mild to moderate COVID-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

Neutralizing activity of BNT162b2-elicited serum

SARS-CoV-2 variants and ending the COVID-19 pandemic